Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of single-agent amrubicin in refractory or early relapsing extensive-stage small cell lung cancer
2006-004785-14Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amrubicin in small cell lung cancer (SCLC), sponsored by Celgene Corporation. Primary endpoint: Objective tumor response rate. Started Sep 2006; status: completed.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-004785-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004785-14.